Fragment optimization and elaboration strategies - the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits.

Saved in:
Bibliographic Details
Title: Fragment optimization and elaboration strategies - the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits.
Authors: Smith CR; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com., Kulyk S; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com., Ahmad MUD; ZoBio BV J. H. Oortweg 19 2333 CH Leiden Netherlands., Arkhipova V; ZoBio BV J. H. Oortweg 19 2333 CH Leiden Netherlands., Christensen JG; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com., Gunn RJ; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com., Ivetac A; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com., Ketcham JM; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com., Kuehler J; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com., Lawson JD; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com., Thomas NC; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com., Wang X; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com., Marx MA; Mirati Therapeutics San Diego California 92121 USA smithc@mirati.com kulyks@mirati.com.
Source: RSC medicinal chemistry [RSC Med Chem] 2022 Sep 27; Vol. 13 (12), pp. 1549-1564. Date of Electronic Publication: 2022 Sep 27 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: Royal Society of Chemistry Country of Publication: England NLM ID: 101759460 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-8682 (Electronic) Linking ISSN: 26328682 NLM ISO Abbreviation: RSC Med Chem Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2632-8682
DOI:10.1039/d2md00163b